InsiderTrades

Form 4 for ACRV Acrivon Therapeutics, Inc.

Accepted 2026-02-18 00:00:00 ET · period of report 2026-02-14 · accession 0000905148-26-000934 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
I 2026-02-18 2026-02-14 ACRV Blume-Jensen Peter Pres, CEO, Dir F - Tax $1.63 -579 314.1K -0.2% -$943.77
2026-02-18 2026-02-14 ACRV Blume-Jensen Peter Pres, CEO, Dir F - Tax $1.63 -1,302 2.09M -0.1% -$2,122

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-02-14 F D 579 $1.63 314,127 I — —
2 Common Common Stock 2026-02-14 F D 1,302 $1.63 2,094,469 D See Footnote — — (F2) These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson?s spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. (F3) These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen?s spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.